The unique water–only extraction process that produces MGX–008 from Pinus radiata bark is environmentally friendly and gives MGX–008 a specific and biologically active makeup.
MGX-008
MGX–008 is a derivative of an extract of the bark of Pinus radiata (Monterey Pine). It is a novel class of botanical therapeutic compounds that represent a new approach to preventing migraine headaches. It has been developed through a substantial number of scientific and clinical studies including 8 human and animal trials. Produced for Migco in a new dedicated $3m plant, it is based on a readily available raw material. MGX–008 is exceptionally consistent, stable and scalable through to commercial availability.
As a polymolecular compound, MGX-008 is progressing through the regulatory process toward approval as a prescription drug.
The unique water–only extraction process to produce MGX–008 is environmentally friendly and gives MGX–008 a specific and biologically active makeup. The process has been exclusively licensed to Migco and is covered by United States and worldwide patents.
Migco also has issued and pending patents for MGX–008 for treatment of migraine.
This double layer of patents–process and method, use, compound–combined with proprietary production knowledge underpins the investment in drug development.
